Pharmacoepidemiology and pharmacogenetics of antidepressant treatment for depressive disorders

Pharmacoepidemiology and pharmacogenetics of antidepressant treatment for depressive disorders (PEGAD) - PEGAD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-005100-99-FI

Enrollment

1000

Registered

2018-06-11

Start date

2018-06-14

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression (ICD-10 F32 and F33). Clinically diagnosed depression (F32-33), with symptom severity equaling or exceeding score 10 in the Patient Health Questionnaire (PHQ-9)

Interventions

Trade Name: All antidepressants (ATC: N06A) marketed in Finland, including all their trade names Pharmaceutical Form:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 700 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 300

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026